MasterPharm Recalls D-Biotin 300 mg Capsules Due to Processing Control Deficiencies
MasterPharm LLC is recalling D-Biotin 300 mg capsules nationwide due to a lack of processing controls that ensures conformity to specifications.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, but the source text explicitly states no illnesses or injuries have been reported, and the hazard is a theoretical lack of processing controls rather than a confirmed high-risk pathogen or structural defect.
Plain-English summary
MasterPharm LLC is voluntarily recalling D-Biotin 300 mg Capsules, 90 capsules per bottle, distributed nationwide in the U.S. The recall was initiated because of a lack of processing controls, which means there is a lack of assurance that the product conforms to its specifications.
The affected product is identified by the following codes: 01-07-2020:12@6, BUD 7/5/2020 and 01-23-2020:00@6, BUD 7/21/2020. The source text does not specify the total number of units recalled or report any illnesses or injuries associated with the product.
Consumers who have purchased this product should stop using it and contact MasterPharm LLC at (866) 630-5600 for further instructions or a refund.
The recalled product
- Product
- D-Biotin 300 mg Capsule, 90 capsules per bottle, MasterPharm, 115-02 Liberty Ave, Richmond Hill, NY 11419, (866) 630-5600
- Manufacturer
- MasterPharm LLC
- Category
- Drug — Dietary Supplement
- Hazard
- Affected units
- 390
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- 01-07-2020:12@6
- BUD 7/5/2020 01-23-2020:00@6
- BUD 7/21/2020
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 26 recalled by MasterPharm LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 26 products in this recall →Related recalls
Same manufacturer · MasterPharm LLC
See all →- ModerateMasterPharm Recalls Tadalafil 12 mg Capsules Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Progesterone Troches Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Calcium Citrate Powder Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Formula 82M Due to Lack of Processing Controls
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Progesterone Troches Due to Lack of Processing Controls
FDA (Drugs) · 2020-08-05
Same hazard · quality control
See all →- HighBaxter Recalls CARDENE IV Nicardipine Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls MYXREDLIN Insulin Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- SevereMasterPharm Recalls Compounded Minoxidil, Biotin, and Spironolactone Capsules
FDA (Drugs) · 2020-07-08
- SevereMasterPharm Recalls Finasteride Plus Capsules Due to Minoxidil Contamination
FDA (Drugs) · 2020-05-20
- ModerateDiethylstilbestrol Capsules Recalled for Lack of Processing Control
FDA (Drugs) · 2020-04-22
- ModerateBetahistine 16 mg Capsules Recalled for Lack of Processing Control
FDA (Drugs) · 2020-04-22
- HighKroger Recalls Capecitabine Tablets Due to Lack of Processing Controls
FDA (Drugs) · 2018-05-16
- HighPrescription Rifampin Capsules Recalled Due to Failed Quality Specifications
FDA (Drugs) · 2023-01-25